These results raise several questions, namely whether: anti-RNP antibodies were an intermittent finding and had no relation to therapy; therapy was concealing clinical manifestations that would otherwise occur and enable evolution into a well-defined ARD; if the “MCTD-stable” patients fulfilled other ARD criteria and, in fact, had an well-defined ARD. Here, RNPC3 is linked to mixed connective tissue disease.